Duchenne Muscular Dystrophy: Opportunity Analysis and Forecast to 2033
Summary
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the DMD market through 2033.
Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Dystrophin is part of a group of proteins, which together form the dystrophin-associated protein complex (DPC). These proteins form a transmembrane scaffold that is crucial for the structure of the muscle tissue, protecting muscle fibers from injury during muscle contraction and relaxation. DMD is an X-linked recessive disorder mainly affecting males, with female carriers.
The DMD market across the 7MM was valued at $2.3 billion in 2023. Over the 10-year forecast period, the market is projected to grow at a CAGR of 8.5%, reaching $5.2 billion by 2033. The major driver for this growth will be the launch of several pipeline agents: Roche’s gene therapy, Capricor’s cell therapy deramiocel, PTC Therapeutics’ ataluren in the US, and other first-in-class therapies.
Key Highlights
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook